1-7 of 7
Wayne Rackoff
Close
Sort by
Journal Articles

Polymorphisms in the Multiple Drug Resistance Protein 1 and in P-Glycoprotein 1 Are Associated with Time to Event Outcomes in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Bortezomib and Pegylated Liposomal Doxorubicin.

Gabriele Buda, M.D., Deborah Ricci, Ph.D., Nadine Cohen, Ph.D., Reyna Favis, Ph.D., C. Chris Huang, Ph.D., Wayne Rackoff, M.D., Sen H. Zhuang, M.D., Ph.D., Jean Luc Harrouseau, M.D., Pieter Sonneveld, M.D., Ph.D., Joan Blade, M.D., Robert Z. Orlowski, M.D., Ph.D.
Journal: Blood
Blood (2009) 114 (22): 109.
https://doi.org/10.1182/blood.V114.22.109.109
Published: 2009
Journal Articles

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia

Clinical Trials & Observations
Jean-Luc Harousseau, Jeffrey E. Lancet, Josy Reiffers, Bob Lowenberg, Xavier Thomas, Francoise Huguet, Pierre Fenaux, Steven Zhang, Wayne Rackoff, Peter De Porre, Richard Stone
Journal: Blood
Blood (2007) 109 (12): 5151–5156.
https://doi.org/10.1182/blood-2006-09-046144
Published: 2007
Journal Articles

Identification of Molecular Predictors of Response to ZARNESTRA™ (Tipifarnib, R115777) in Relapsed and Refractory Acute Myeloid Leukemia.

Mitch Raponi, Bob Lowenberg, Jeffrey E. Lancet, Jean-Luc Harousseau, Richard Stone, Wayne Rackoff, Alain Thibault, Yi Zhang, David Atkins, Yixin Wang
Journal: Blood
Blood (2004) 104 (11): 861.
https://doi.org/10.1182/blood.V104.11.861.861
Published: 2004
Journal Articles

A Phase I Study of Tipifarnib in Combination with Imatinib Mesylate (IM) for Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Who Failed IM Therapy.

Jorge Cortes, M.D., Guillermo Garcia-Manero, M.D., Susan O’Brien, M.D., Ingrid Hernandez, R.N., Wayne Rackoff, M.D., Stefan Faderl, M.D., Deborah Thomas, M.D., Alessandra Ferrajoli, M.D., Moshe Talpaz, M.D., Hagop Kantarjian, M.D.
Journal: Blood
Blood (2004) 104 (11): 1011.
https://doi.org/10.1182/blood.V104.11.1011.1011
Published: 2004
Journal Articles

Influence of Hemoglobin Response to Epoetin Alfa on Quality-of-Life in Anemic Children with Cancer Receiving Myelosuppressive Chemotherapy.

Bassem I. Razzouk, MD, Marilyn Hockenberry, PhD, PNP, Pamela S. Hinds, RN, PhD, James Feusner, MD, Wayne Rackoff, MD, Jeffrey D. Hord, MD
Journal: Blood
Blood (2004) 104 (11): 2218.
https://doi.org/10.1182/blood.V104.11.2218.2218
Published: 2004
Journal Articles

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

Clinical Trials & Observations
Jorge Cortes, Maher Albitar, Deborah Thomas, Francis Giles, Razelle Kurzrock, Alain Thibault, Wayne Rackoff, Charles Koller, Susan O'Brien, Guillermo Garcia-Manero, Moshe Talpaz, Hagop Kantarjian
Journal: Blood
Blood (2003) 101 (5): 1692–1697.
https://doi.org/10.1182/blood-2002-07-1973
Published: 2003
Journal Articles

Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group

Clinical Trials & Observations
Beverly J. Lange, Bruce C. Bostrom, Joel M. Cherlow, Martha G. Sensel, Mei K. L. La, Wayne Rackoff, Nyla A. Heerema, Robert S. Wimmer, Michael E. Trigg, Harland N. Sather
Journal: Blood
Blood (2002) 99 (3): 825–833.
https://doi.org/10.1182/blood.V99.3.825
Published: 2002